Clinical implications of activated leukocyte cell adhesion molecule expression in breast cancer

[1]  C. Bendixen,et al.  Molecular cloning, characterization and developmental expression of porcine β-synuclein , 2010, Molecular Biology Reports.

[2]  K. Kimbro,et al.  A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment , 2008, Molecular Biology Reports.

[3]  R. Wirtz,et al.  Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer , 2008, Breast Cancer Research and Treatment.

[4]  W. Weichert,et al.  Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer , 2006, Journal of Clinical Pathology.

[5]  P. Willems,et al.  Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. , 2005, Cancer research.

[6]  G. Swart,et al.  Activated leukocyte cell adhesion molecule (ALCAM/CD166): Signaling at the divide of melanoma cell clustering and cell migration? , 2005, Cancer and Metastasis Reviews.

[7]  Troy Stevens,et al.  Open Access Activated Leukocyte Cell Adhesion Molecule in Breast Cancer: Prognostic Indicator , 2022 .

[8]  G. Watkins,et al.  Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer. , 2004, European journal of cancer.

[9]  C. Isaacs,et al.  Prognostic Factors in Breast Cancer: Current and New Predictors of Metastasis , 2001, Journal of Mammary Gland Biology and Neoplasia.

[10]  I. Ellis,et al.  Prognostic and predictive factors in primary breast cancer and their role in patient management: The Nottingham Breast Team. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  J. Bajorath,et al.  Cell surface receptors and their ligands: In vitro analysis of CD6‐CD166 interactions , 2000, Proteins.

[12]  S Kumar,et al.  Human bone marrow stromal cell: coexpression of markers specific for multiple mesenchymal cell lineages. , 2000, Blood cells, molecules & diseases.

[13]  J. Schalken,et al.  Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alpha-catenin. , 2000, Biochemical and biophysical research communications.

[14]  K. Milde-Langosch,et al.  Expression pattern of the AP‐1 family in breast cancer: Association of fosB expression with a well‐differentiated, receptor‐positive tumor phenotype , 1999, International journal of cancer.

[15]  J. Stephan,et al.  Distribution and function of the adhesion molecule BEN during rat development. , 1999, Developmental biology.

[16]  Y. van Kooyk,et al.  MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). , 1998, The American journal of pathology.

[17]  Y. Totsuka,et al.  Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with Adriamycin , 2004, Clinical & Experimental Metastasis.

[18]  S. Loening,et al.  ALCAM/CD166 is up‐regulated in low‐grade prostate cancer and progressively lost in high‐grade lesions , 2003, The Prostate.